Treatment interventions for Parkinson's disease: an evidence based assessment
- PMID: 12047983
- DOI: 10.1016/S0140-6736(02)08520-3
Treatment interventions for Parkinson's disease: an evidence based assessment
Abstract
We did a systematic review, with a uniform method of assessment of efficacy and safety, to assess the different interventions available for the management of Parkinson's disease (drugs, surgical interventions, and physical treatments) with respect to the following indications: prevention of disease progression, symptomatic treatment of motor features (parkinsonism), symptomatic control of motor complications, prevention of motor complications, and symptomatic treatment of non-motor features. Our aim was not to define practice guidelines, but rather to improve clinicians' knowledge of the presently available published clinical evidence, based mainly on randomised controlled trials. We hope that our review will help doctors to incorporate this background into their own decision-making strategy to make appropriate choices with respect to the treatment of individual patients with Parkinson's disease.
Comment in
-
Review: several drugs are efficacious for symptomatic treatment of Parkinson disease.ACP J Club. 2003 Jan-Feb;138(1):14. ACP J Club. 2003. PMID: 12511126 No abstract available.
Similar articles
-
Individual-level interventions to reduce personal exposure to outdoor air pollution and their effects on people with long-term respiratory conditions.Cochrane Database Syst Rev. 2021 Aug 9;8(8):CD013441. doi: 10.1002/14651858.CD013441.pub2. Cochrane Database Syst Rev. 2021. PMID: 34368949 Free PMC article.
-
Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.Cochrane Database Syst Rev. 2018 Apr 24;4(4):CD008201. doi: 10.1002/14651858.CD008201.pub3. Cochrane Database Syst Rev. 2018. PMID: 29687454 Free PMC article.
-
Personally tailored activities for improving psychosocial outcomes for people with dementia in long-term care.Cochrane Database Syst Rev. 2018 Feb 13;2(2):CD009812. doi: 10.1002/14651858.CD009812.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2023 Mar 13;3:CD009812. doi: 10.1002/14651858.CD009812.pub3. PMID: 29438597 Free PMC article. Updated.
-
The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on 'Off'-time in Patients with Advanced Parkinson's Disease: A Systematic Review.Adv Ther. 2021 Jun;38(6):2854-2890. doi: 10.1007/s12325-021-01747-1. Epub 2021 May 20. Adv Ther. 2021. PMID: 34018146 Free PMC article.
-
Providing physicians with feedback on medication adherence for people with chronic diseases taking long-term medication.Cochrane Database Syst Rev. 2018 Jan 10;1(1):CD012042. doi: 10.1002/14651858.CD012042.pub2. Cochrane Database Syst Rev. 2018. PMID: 29320600 Free PMC article.
Cited by
-
A deep learning approach for prediction of Parkinson's disease progression.Biomed Eng Lett. 2020 Apr 16;10(2):227-239. doi: 10.1007/s13534-020-00156-7. eCollection 2020 May. Biomed Eng Lett. 2020. PMID: 32477610 Free PMC article.
-
Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Transl Neurodegener. 2020 Oct 16;9(1):39. doi: 10.1186/s40035-020-00218-x. Transl Neurodegener. 2020. PMID: 33066808 Free PMC article. Review.
-
Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.CNS Drugs. 2010 Nov;24(11):941-68. doi: 10.2165/11537810-000000000-00000. CNS Drugs. 2010. PMID: 20932066 Review.
-
Prodromal non-motor symptoms of Parkinson's disease.Neuropsychiatr Dis Treat. 2007 Feb;3(1):145-52. doi: 10.2147/nedt.2007.3.1.145. Neuropsychiatr Dis Treat. 2007. PMID: 19300544 Free PMC article.
-
Plasma-Enabled Carbon Nanostructures for Early Diagnosis of Neurodegenerative Diseases.Materials (Basel). 2014 Jun 25;7(7):4896-4929. doi: 10.3390/ma7074896. Materials (Basel). 2014. PMID: 28788112 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical